Search Within

Department of Medicine

Formats
  1. Journal Article (19572)
  2. Meeting Abstract (16038)
  3. Review (1147)
  4. Book Section (934)
  5. Editorial (607)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (235)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22311)
  2. Hematologic Malignancies, Division of (13264)
  3. Center for Hematologic Malignancies (11049)
  4. GSK Faculty (10640)
  5. Survivorship Research (9323)
  6. Division of Subspecialty Medicine (7531)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1068)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1043)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3721)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6456)
  2. Elsevier Inc. (4213)
  3. American Society of Hematology (4000)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2109)

More Publishers

Results (39594)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes
    Meeting Abstract

    Attard, G.; Agarwal, N.; Graff, J. N.; Sandhu, S.; Efstathiou, E.; Özgüroğlu, M.; de Santana Gomes, A. J. P.; Vianna, K. C. M.; Luo, H.; Cheng, H. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance)
    Meeting Abstract

    Char, S. K.; Shi, Q.; Zemla, T.; Ma, C.; Cheng, E.; Kumthekar, P.; Guthrie, K. A.; Couture, F.; Kuebler, J. P.; Kumar, P.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses
    Meeting Abstract

    Elez, E.; Yoshino, T.; Shen, L.; Lonardi, S.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors
    Meeting Abstract

    Chung, V.; Kochenderfer, M. D.; Natarajan, N.; Williams, G. R.; Laursen, A. A.; Cockrum, P.; Rhodes, W.; Surinach, A.; Zhang, L.; Li, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers
    Meeting Abstract

    Schreck, K. C.; De La Fuente, M. I.; Rine, J.; Kline, I.; Shephard, S. P.; Ahnert, J. R.; Sherman, E. J.; Yaeger, R.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)
    Meeting Abstract

    Sinicrope, F. A.; Ou, F. S.; Arnold, D.; Peters, W.; Behrens, R. J.; Lieu, C. H.; Matin, K.; Cohen, D. J.; Potter, S. L.; Frankel, W. L.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study
    Meeting Abstract

    Hamilton, E. P.; De Laurentiis, M.; Jhaveri, K. L.; Hu, X.; Ladoire, S.; Patsouris, A.; Zamagni, C.; Cui, J.; Cazzaniga, M.; Cil, T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)
    Meeting Abstract

    Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; Muro, K.; Molena, D.; Van Cutsem, E.; Hyung, W. J.; Wyrwicz, L.; Oh, D.; Omori, T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)
    Meeting Abstract

    Traina, T. A.; Chen, Y.; Khoury, K.; Rugo, H. S.; Mayer, E. L.; Abdou, Y.; Melisko, M. E.; Pareja, F.; Weigelt, B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Addressing clinical trial barriers in lung cancer: Patient-reported impact of resources on trial participation
    Meeting Abstract

    Preeshagul, I. R.; Das, D. G.; Arfe, A.; Awad, M. M.; Feldman, J. L.; Conneran, T.; Horn, M. K.; Singhi, E. K.; Daly, R. M.; Wozniak, A. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save